Ranexa
NDC Package 67159-112-03

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Ranexa is ranolazine is used to treat a certain type of chest pain (chronic stable angina). Marketed by Gilead Palo Alto, Inc., this product is identified by NDC 67159-112 and is authorized under FDA application NDA021526.

Identification & Billing

NDC Package Code
67159-112-03
Package Description
60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC
Product Code
67159-112
11-Digit Billing Format
67159011203

Clinical Specifications

Proprietary Name
Ranexa
Dosage Form
-
Usage Information
Ranolazine is used to treat a certain type of chest pain (chronic stable angina). It decreases the number of times you may get chest pain. Relieving symptoms of angina can increase your ability to exercise and perform strenuous work. Ranolazine works differently than other drugs for angina, so it can be used with your other angina medications (including nitrates, calcium channel blockers such as amlodipine, beta blockers such as metoprolol). It is thought to work by improving how well the heart uses oxygen so that it can do more work with less oxygen.

Regulatory & Marketing

Labeler Name
Gilead Palo Alto, Inc.
FDA Application #
NDA021526
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
01-27-2006
End Marketing Date
03-31-2013
Listing Expiration
03-31-2013
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67159-112-03 identifies a specific commercial package of 60 tablet, film coated, extended release in 1 bottle, plastic of Ranexa, labeled by Gilead Palo Alto, Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Gilead Palo Alto, Inc. on January 27, 2006. The current certification is valid through March 31, 2013.

What are the primary indications for this medication?

Ranolazine is used to treat a certain type of chest pain (chronic stable angina). It decreases the number of times you may get chest pain. Relieving symptoms of angina can increase your ability to exercise and perform strenuous work. Ranolazine works differently than other drugs for angina, so it can be used with your other angina medications (including nitrates, calcium channel blockers such as amlodipine, beta blockers such as metoprolol). It is thought to work by improving how well the heart uses oxygen so that it can do more work with less oxygen.

How is this Gilead Palo Alto, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67159011203. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
67159-112-03
11-Digit CMS (5-4-2)
67159-0112-03

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.